Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Other Accumulated Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Other Accumulated Expenses for 2 consecutive years, with $364000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 36.33% to $364000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $364000.0 through Dec 2025, up 36.33% year-over-year, with the annual reading at $364000.0 for FY2025, 36.33% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $364000.0 at Evommune, down from $371000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $371000.0 in Q3 2025, with the low at $267000.0 in Q4 2024.